EP1363993A4 - METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) - Google Patents

METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)

Info

Publication number
EP1363993A4
EP1363993A4 EP02714815A EP02714815A EP1363993A4 EP 1363993 A4 EP1363993 A4 EP 1363993A4 EP 02714815 A EP02714815 A EP 02714815A EP 02714815 A EP02714815 A EP 02714815A EP 1363993 A4 EP1363993 A4 EP 1363993A4
Authority
EP
European Patent Office
Prior art keywords
ikk
kinase
inhibitors
methods
treating inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02714815A
Other languages
German (de)
French (fr)
Other versions
EP1363993A2 (en
Inventor
James R Burke
Steven Nadler
Yuping Qiu
Robert M Townsend
Fred Christopher Zusi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,977 external-priority patent/US6960585B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1363993A2 publication Critical patent/EP1363993A2/en
Publication of EP1363993A4 publication Critical patent/EP1363993A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP02714815A 2001-02-01 2002-02-01 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) Withdrawn EP1363993A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26585301P 2001-02-01 2001-02-01
US265853P 2001-02-01
US965977 2001-09-27
US09/965,977 US6960585B2 (en) 2000-10-03 2001-09-27 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
PCT/US2002/003060 WO2002060386A2 (en) 2001-02-01 2002-02-01 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)

Publications (2)

Publication Number Publication Date
EP1363993A2 EP1363993A2 (en) 2003-11-26
EP1363993A4 true EP1363993A4 (en) 2008-11-12

Family

ID=26951465

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02714815A Withdrawn EP1363993A4 (en) 2001-02-01 2002-02-01 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)

Country Status (10)

Country Link
EP (1) EP1363993A4 (en)
JP (1) JP2004529088A (en)
AU (1) AU2002247059B2 (en)
CA (1) CA2436770A1 (en)
CZ (1) CZ20032287A3 (en)
HU (1) HUP0304045A3 (en)
MX (1) MXPA03006817A (en)
NO (1) NO20033429L (en)
PL (1) PL364111A1 (en)
WO (1) WO2002060386A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117835T2 (en) * 2000-10-03 2006-10-19 Bristol-Myers Squibb Co. Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and drugs containing them
DE60133758T2 (en) 2000-10-26 2009-07-02 Amgen Inc., Thousand Oaks ANTIPHLOGISTIC MEANS
AR037641A1 (en) 2001-12-05 2004-11-17 Tularik Inc INFLAMMATION MODULATORS
DE10237722A1 (en) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indole or benzimidazole derivatives for the modulation of IKappaB kinase
CA2502429A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
TW200616967A (en) 2004-06-24 2006-06-01 Smithkline Beecham Corp Novel indazole carboxamides and their use
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
NZ563687A (en) 2005-06-30 2011-07-29 Smithkline Beecham Corp 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta)
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CA2621057A1 (en) * 2005-09-07 2007-03-15 Laboratoires Serono S.A. Ikk inhibitors for the treatment of endometriosis
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
KR101563103B1 (en) * 2006-12-13 2015-10-23 아스카 세이야쿠 가부시키가이샤 Quinoxaline derivative
AR065804A1 (en) 2007-03-23 2009-07-01 Smithkline Beecham Corp COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR20130097813A (en) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 Auris formulations for treating otic diseases and conditions
WO2010000903A2 (en) * 2008-06-30 2010-01-07 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) Composition capable of modulating ikkalpha activity for the treatment of diseases associated with acantholysis
KR101323448B1 (en) 2008-10-02 2013-11-27 아사히 가세이 파마 가부시키가이샤 8-substituted isoquinoline derivative and use thereof
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
KR20190024983A (en) 2016-06-29 2019-03-08 오토노미, 인코포레이티드 Triglyceride ear preparations and uses thereof
EP3494994A1 (en) * 2017-12-07 2019-06-12 Universität zu Köln Combinations of ripk1- and ikk-inhibitors for the prevention or treatment of immune diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028860A2 (en) * 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160097A (en) * 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6030834A (en) * 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
PL357284A1 (en) * 2000-03-15 2004-07-26 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028860A2 (en) * 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSAI S -H ET AL: "Suppression of TNF[alpha]-mediated NF[kappa]B activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells", JOURNAL OF CELLULAR BIOCHEMISTRY 19990915 US, vol. 74, no. 4, 15 September 1999 (1999-09-15), pages 606 - 615, XP002497486, ISSN: 0730-2312 *

Also Published As

Publication number Publication date
HUP0304045A2 (en) 2004-04-28
CZ20032287A3 (en) 2004-02-18
EP1363993A2 (en) 2003-11-26
AU2002247059B2 (en) 2006-11-16
CA2436770A1 (en) 2002-08-08
NO20033429D0 (en) 2003-07-31
JP2004529088A (en) 2004-09-24
PL364111A1 (en) 2004-12-13
NO20033429L (en) 2003-09-24
MXPA03006817A (en) 2003-11-13
WO2002060386A3 (en) 2002-10-10
WO2002060386A2 (en) 2002-08-08
HUP0304045A3 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
EP1363993A4 (en) METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
GB2393202B (en) Methods of well treatment
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1444204A4 (en) Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
EP1383743A4 (en) Dual inhibitors of pde 7 and pde 4
IL161775A0 (en) Topical compositions and methods for treatment of adverse effects ofionizing radiation
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
HK1080382A1 (en) Compositions and methods for treatment of hyperplasia
EP1363702A4 (en) Methods of inhibiting kinases
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
ZA200201161B (en) Methods of treating nuclear factor-kappa B mediated diseases and disorders.
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
NO20043085L (en) Methods and compositions for the treatment of central nervous system disorders
NO20033854D0 (en) N-but-3-enyl-norbuprenorphine and methods of use
EP1520043A4 (en) METHODS FOR THE IDENTIFICATION OF IKKa FUNCTION AND OTHER GEN ES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES
EP1424897A4 (en) Compositions and methods for treatment of cancer
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1416795A4 (en) Compositions and methods for treatment of mitochondrial diseases
EP1515707A4 (en) Method of treating atherosclerosis and other inflammatory diseases
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1472273A4 (en) Compositions and methods for the treatment of immune related diseases
EP1562587A4 (en) Novel compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030829

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALI20080930BHEP

Ipc: A61P 29/00 20060101ALI20080930BHEP

Ipc: A61K 31/519 20060101ALI20080930BHEP

Ipc: A61K 31/4985 20060101ALI20080930BHEP

Ipc: A61K 31/4745 20060101ALI20080930BHEP

Ipc: C07D 487/04 20060101ALI20080930BHEP

Ipc: C12N 15/54 20060101ALI20080930BHEP

Ipc: C12N 9/12 20060101ALI20080930BHEP

Ipc: C12N 5/10 20060101ALI20080930BHEP

Ipc: C12N 1/21 20060101AFI20030912BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20081010

17Q First examination report despatched

Effective date: 20090205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100209